U.S. Healthcare Services Stock News

Cytokinetics (NasdaqGS:CYTK) presented new clinical data on MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy at a major cardiology conference. The updates covered exercise capacity outcomes, effectiveness across patients with and without hypertension, and safety during treatment interruption and restart. The new analyses expand the clinical profile of MYQORZO, a recently approved oHCM therapy, and add detail on how the drug performs in real treatment scenarios. Cytokinetics...

Wondering whether ServisFirst Bancshares is attractively priced at its current level? This article focuses squarely on what the recent share performance might be telling you about value. The stock last closed at US$73.73, with returns of 2.7% year to date, a 14.4% decline over the past month, and a 9.7% decline over the past year, while still showing a 35.2% gain over three years and 31.1% over five years. These mixed returns have kept ServisFirst Bancshares on the radar for investors who...

Wondering whether DocuSign at around US$46.82 still lines up with what you would consider a fair price? This article walks through the key valuation checks so you can put the current share price in context. The stock has seen a mixed run recently, with a 3.8% decline over the last 7 days, a 4.5% gain over the last 30 days, and year to date and 1 year returns of 27.8% and 43.9% declines respectively. Recent headlines have continued to focus on DocuSign's role in digital agreement workflows...

Gold.com (NYSE:GOLD) has appointed Juan Sartori to its Board of Directors with immediate effect. The move coincides with the retirement of longtime director Beverley Lepine after more than a decade of service. Sartori brings experience in digital finance, commodities, and global capital markets to the company’s board. Gold.com, trading at $46.72, has seen a 34.4% return year to date and a 72.0% return over the past year, with longer term 3 year and 5 year returns of 74.1% and 183.2%...

LyondellBasell recently announced that David Dennison, a nearly 30‑year industry veteran who joined the company in 2007 and most recently served as a vice president in its Circular and Low Carbon Solutions business, will become head of investor relations in May 2026, succeeding retiring long‑time executive Dave Kinney. Dennison’s background in planning, commercial leadership and circular solutions could meaningfully shape how LyondellBasell communicates its transition toward recycling,...

In early March 2026, AvePoint announced the past general availability of its AgentPulse Command Center, expanding multicloud observability and governance for autonomous AI agents across Microsoft 365 and Google Cloud, with unified monitoring, lifecycle management, and cost controls to reduce shadow AI, data exposure, and surprise usage bills. A distinctive feature is the single-pane view across Copilot Studio, Microsoft Foundry, SharePoint agents, and Vertex AI, giving enterprises...

Live Nation Entertainment has settled the US Department of Justice’s antitrust lawsuit without admitting wrongdoing, extending its consent decree by eight years and setting up a US$280 million fund to address state damages claims. The agreement lets Live Nation retain Ticketmaster under stricter operating conditions while leaked internal messages and ongoing state actions keep its ticketing practices under intense scrutiny. We’ll now examine how the extended DOJ consent decree and continuing...

Frontdoor (FTDR) is back in focus after reporting Q4 revenue of $433 million, a 13.1% year over year increase, along with earnings that exceeded expectations and full year revenue guidance slightly below projections. See our latest analysis for Frontdoor. Since the earnings release, Frontdoor’s share price has moved to US$64.22, with a 13.38% 1 month share price return and a 69.58% 1 year total shareholder return, which may suggest building momentum despite some recent short term pullback. If...

In March 2026, Oklo Inc. and Centrus Energy agreed to pursue a joint venture for high-assay low-enriched uranium deconversion at Centrus’ Piketon, Ohio site, while Centrus also reported lower-than-expected quarterly earnings affected by a delayed Russian shipment and outlined increased capital spending plans. Centrus’ recent collaboration with Palantir on AI-driven enrichment optimization and its talks with Oklo on an integrated HALEU hub highlight how technology and fuel-cycle partnerships...

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...

O'Reilly Automotive completed a significant fixed income offering of senior unsecured notes due in 2036. The transaction adds long dated debt to the company’s balance sheet, which may affect its capital structure and liquidity profile. The terms of the notes and investor demand can offer clues about how credit markets currently view O'Reilly Automotive, ticker NasdaqGS:ORLY. Investors watching NasdaqGS:ORLY now have a fresh data point to consider alongside the current share price of $90.46...

Dentsply Sirona and Siemens Healthineers recently received US FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental‑dedicated MRI system clinically validated for multiple specialties including endodontics, periodontics, TMJ, orthodontics, and tooth extraction. This non‑ionizing, dental‑specific MRI platform, with a focused field of view and sub‑20‑minute workflow, could meaningfully enhance complex diagnostic capabilities in hospitals, large clinics, and academic...

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...

Event driven setup around Flowers Foods Recent commentary around Flowers Foods (FLO) focuses on its large Q4 non cash impairment charge, which has stirred investor skepticism even as some market watchers argue the stock reaction looks harsher than the underlying fundamentals. See our latest analysis for Flowers Foods. At a share price of $8.89, Flowers Foods has seen a 14.2% decline over the past month and a 19.3% decline over the past quarter on a share price return basis. The 1 year total...

AI partnership expansion with Google Cloud comes into focus Waystar Holding (WAY) is back on investor radars after announcing an expanded collaboration with Google Cloud that centers on deeper use of Gemini AI models and data infrastructure in healthcare payments. The move targets more automation across complex revenue cycle workflows, including new agentic AI use cases that combine financial and clinical data, and could influence how investors think about the company’s long term technology...

Ituran Location and Control Ltd. recently reported higher fourth‑quarter and full‑year 2025 earnings, approved a US$1.50 per‑share cash dividend totaling about US$30.00 million to be paid on April 16, 2026, and completed a US$25.42 million share buyback while authorizing an additional US$10.00 million for repurchases. The combination of earnings growth, a sizable dividend drawn from “Preferred Income” and “Preferred Technological Income” at a reduced 20% withholding tax rate, and an expanded...

Dyne Therapeutics recently advanced its neuromuscular pipeline, initiating the global Phase 3 HARMONIA trial of z-basivarsen for myotonic dystrophy type 1 and releasing new 24‑month data from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, alongside reporting a full-year 2025 net loss of US$446.21 million. With FDA alignment on HARMONIA’s confirmatory design, multiple regulatory designations for both assets, and additional long-term cardiopulmonary data in DMD,...

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...

Why TriMas is on investors’ radar today TriMas (TRS) has drawn fresh interest as investors look at its recent share performance alongside its value score of 3 and current market capitalization of about US$1.32b. The stock shows a 1 day return of 1.23%, a month return decline of 2.21%, and a past 3 months return of 3.77%, while the 1 year total return stands at 42.54%. See our latest analysis for TriMas. The recent 1 day share price gain of 1.23% to US$35.47 comes after a weaker 7 day and year...

If you are wondering whether LTC Properties at around US$38.99 is offering good value today, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock has delivered a 0.6% return over the last week, a 1.0% decline over the past month, and is up 12.5% year to date and 15.5% over the past year, with longer term returns of 41.0% over three years and 26.1% over five years. Recent attention on LTC Properties has focused on its position...

Consolidated Edison recently entered into a new US$3.50 billions revolving credit facility to support its commercial paper programs and general corporate purposes, shortly after reporting Q4 2025 revenue and adjusted EPS that topped Wall Street expectations. Together with management’s plans for a five-year adjusted EPS compound annual growth rate of 6% to 7%, the expanded credit access highlights how the utility is prioritizing both liquidity and earnings visibility. We’ll now look at how...

KE Holdings (NYSE:BEKE) FY 2025 Results Overview KE Holdings (NYSE:BEKE) has wrapped up FY 2025 with fourth quarter revenue of C¥22.2b and basic EPS of C¥0.08, alongside trailing 12 month revenue of C¥94.6b and basic EPS of C¥2.70 that frame the latest print for investors watching the stock around C¥16.90 per share. The company has seen quarterly revenue range from C¥22.1b to C¥26.0b over the past year, with basic EPS moving between C¥0.08 and C¥1.16 across FY 2025. This gives a clearer view...

Earlier this month, AbbVie reported positive Phase 1 multiple-ascending-dose results for its investigational obesity drug ABBV-295, a long-acting amylin analog that induced clinically meaningful, dose-dependent weight loss with generally mild gastrointestinal side effects over 12–13 weeks of treatment. The data highlight AbbVie’s push into a mechanistically distinct class of obesity therapies beyond incretin-based drugs, adding another potential pillar to its already broad pipeline in...

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...